Kaken Pharmaceutical Co., Ltd. (4521) Earnings: Operating Profit Up 59.8% YoY to 10.9 Billion Yen

Kaken Pharmaceutical Co., Ltd. (4521) announced its financial results, posting a significant 59.8% year-on-year increase in net sales to 30,154 million yen. Profitability also showed strong performance, with operating income reaching 10,902 million yen, ordinary income at 11,258 million yen, and net income attributable to owners of the parent at 8,439 million yen. Earnings per share (EPS) stood at 222.86 yen, while comprehensive income was reported at 8,880 million yen.

From a financial and valuation perspective, the company maintains a robust liquidity position with 50.71 billion yen in cash and cash equivalents, despite operating cash flow registering -11.08 billion yen and free cash flow at -10.76 billion yen. Profitability metrics show a Return on Equity (ROE) of 1.56% and a Return on Assets (ROA) of 1.20%, alongside an EBITDA of 2.16 billion yen. Backed by substantial cash reserves, the company sustains a solid financial foundation while market participants monitor future cash flow trajectories and profitability enhancements.